Heffernan-Stroud Linda A, Obeid Lina M
Department of Medicine, Medical University of South Carolina, Charleston, SC 29425-7790, USA.
Adv Enzyme Regul. 2011;51(1):219-28. doi: 10.1016/j.advenzreg.2010.10.003. Epub 2010 Oct 28.
Both the sphingolipid and p53 pathways are important regulators- and apparent collaborators-of cell-fate decisions. Whereas some investigations have suggested that ceramide and more complex sphingolipids function upstream of p53 or in a p53-independent manner, other studies propose that p53-dependent alterations in these sphingolipids can also contribute to apoptosis. Further studies focusing on sphingolipid metabolizing enzymes have revealed that they function similarly both upstream and downstream of p53 activation. However, whereas various components of the sphingolipid and p53 pathways may simultaneously function to elicit apoptosis and/or growth inhibition, SMase and SK1 may undergo explicit regulation by p53 that could contribute to ceramide-induced senescence in cells. Thus, we propose that regulation of bioactive sphingolipid signaling molecules could be of therapeutic benefit in the treatment of p53-dependent cancers.
鞘脂途径和p53途径都是细胞命运决定的重要调节因子,且明显相互协作。虽然一些研究表明神经酰胺和更复杂的鞘脂在p53上游发挥作用或以不依赖p53的方式发挥作用,但其他研究提出这些鞘脂中依赖p53的改变也可能导致细胞凋亡。进一步针对鞘脂代谢酶的研究表明,它们在p53激活的上游和下游发挥相似的作用。然而,虽然鞘脂途径和p53途径的各种组分可能同时发挥作用以引发细胞凋亡和/或生长抑制,但鞘磷脂酶(SMase)和鞘氨醇激酶1(SK1)可能受到p53的明确调控,这可能导致细胞中神经酰胺诱导的衰老。因此,我们提出,生物活性鞘脂信号分子的调控在治疗p53依赖性癌症方面可能具有治疗益处。